Tero Aittokallio

Identification of subgroups of triple negative breast cancer cells with selective responses to mTOR, CDK, mitotic and proteasome inhibitors (2015)

Cancer Research

Gautam P, Karhinen L, Szwajda A, Jha SK, Yadav B, Aittokallio T, Wennerberg K

(O2 Muu julkaisu )

Identification of drug candidates and repurposing opportunities through compound-target interaction networks (2015)

Expert Opinion on Drug Discovery

Anna Cichonska, Juho Rousu, Tero Aittokallio

(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))

Novel therapeutic possibilities for chemorefractory ovarian cancer patients identified by functional ex vivo drug sensitivity testing of primary cells from ascites (2015)

Cancer Research

Murumagi A, Hirasawa A, Arjama M, Valimaki K, Yadav B, Tang J, Szwajda A, Turunen L, Mpindi JP, Pellinen T, Wennerberg K, Butzow R, Aittokallio T, Kallioniemi I

(O2 Muu julkaisu )

TIMMA-R: an R package for predicting synergistic multi-targeted drug combinations in cancer cell lines or patient-derived samples (2015)

Bioinformatics

He LY, Wennerberg K, Aittokallio T, Tang J

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Toward more realistic drug-target interaction predictions (2015)

Briefings in Bioinformatics

Tapio Pahikkala, Antti Airola, Sami Pietilä, Sushil Shakyawar, Agnieszka Szwajda, Jing Tang, Tero Aittokallio

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Protein phosphatase 2A activity is a major determinant of therapy response in cancer cells (2015)

Cancer Research

Kauko O, Imanishi S, Kaur A, Laajala D, Kulesskiy E, Jumppanen M, Corthals G, Aittokallio T, Wennerberg K, Westermarck J

(O2 Muu julkaisu )

Systematic Mapping of Kinase Addiction Combinations in Breast Cancer Cells by Integrating Drug Sensitivity and Selectivity Profiles (2015)

Chemistry and Biology

Szwajda A, Gautam P, Karhinen L, Jha SK, Saarela J, Shakyawar S, Turunen L, Yadav B, Tang J, Wennerberg K, Aittokallio T

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

High-throughput drug sensitivity and resistance testing of ovarian cancer cell lines provides useful strategy for assessing drug repositioning and therapeutic possibilities of emerging drugs (2015)

Clinical Cancer Research

Hirasawa A, Murumagi A, Arjama M, Yadav B, Mpindi JP, Wennerberg K, Aittokallio T, Aoki D, Kallioniemi O

(O2 Muu julkaisu )

Phosphoproteomics Combined with Quantitative 14-3-3-affinity Capture Identifies SIRT1 and RAI as Novel Regulators of Cytosolic Double-stranded RNA Recognition Pathway (2014)

Molecular and Cellular Proteomics

Ohman T, Soderholm S, Hintsanen P, Valimaki E, Lietzen N, MacKintosh C, Aittokallio T, Matikainen S, Nyman TA

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Stroma- Derived Factors Significantly Impact the Drug Response Profiles of Patient- Derived Primary AML Cells: Implications for Drug Sensitivity Testing (2014)

Blood

Karjalainen R, Pemovska T, Majumder MM, Tamborero D, Yadav B, Kontro M, Gjertsen B, Parsons A, Suvela M, Aittokallio T, Porkka K, Kallioniemi O, Wennerberg K, Heckman CA

(O2 Muu julkaisu )

Ota yhteyttä

Linkit

Julkaisut

Järjestä:

Identification of subgroups of triple negative breast cancer cells with selective responses to mTOR, CDK, mitotic and proteasome inhibitors (2015)

Identification of drug candidates and repurposing opportunities through compound-target interaction networks (2015)

Novel therapeutic possibilities for chemorefractory ovarian cancer patients identified by functional ex vivo drug sensitivity testing of primary cells from ascites (2015)

TIMMA-R: an R package for predicting synergistic multi-targeted drug combinations in cancer cell lines or patient-derived samples (2015)

Toward more realistic drug-target interaction predictions (2015)

Protein phosphatase 2A activity is a major determinant of therapy response in cancer cells (2015)

Systematic Mapping of Kinase Addiction Combinations in Breast Cancer Cells by Integrating Drug Sensitivity and Selectivity Profiles (2015)

High-throughput drug sensitivity and resistance testing of ovarian cancer cell lines provides useful strategy for assessing drug repositioning and therapeutic possibilities of emerging drugs (2015)

Phosphoproteomics Combined with Quantitative 14-3-3-affinity Capture Identifies SIRT1 and RAI as Novel Regulators of Cytosolic Double-stranded RNA Recognition Pathway (2014)

Stroma- Derived Factors Significantly Impact the Drug Response Profiles of Patient- Derived Primary AML Cells: Implications for Drug Sensitivity Testing (2014)